A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : anti-TNF-alpha / anti-tumor necrosis factor-alpha

[Related PubMed/MEDLINE]
Total Number of Papers: 168
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   anti-TNF-alpha  (>> Co-occurring Abbreviation)
Long Form:   anti-tumor necrosis factor-alpha
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis. BD
2022 Anti-tumor necrosis factor-alpha treatment in pediatric patients with pars planitis: a single-center experience from Turkey. 8-24months, ADA, BCVA, CMT, IMAs, PP
2022 Comparative risk of herpes zoster in patients with psoriatic disease on systemic treatments: a systematic review and network meta-analysis. CI, CS, csDMARDs, HZ, NMA, PRISMA
2022 Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet's Disease: A Systematic Review and Meta-Analysis. BD, CI
2022 Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis. anti-NGF, PBS/IC
2022 Paternal use of medications for inflammatory bowel disease and the risk of hospital-diagnosed infections in the offspring: a nationwide cohort study. 5-ASAs, aHR, IBD
2022 Rates of latent and active tuberculosis in BGC vaccinated, immunosuppressed Crohn's disease patients form Bulgaria before and during anti-tumor necrosis factor therapy. ATBI, CD, LTBI, TBI
2022 Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease. CD, IBD, IFX-BioS, UC
2022 Risks of Melanoma and Nonmelanoma Skin Cancers Pre- and Post-Inflammatory Bowel Disease Diagnosis. BCC, CI, IBD, NMSCs, SCC, UC
10  2022 TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis. ADMA, HSPGs, MCP-1, MMP-9, RA, sGAGs, sVCAM-1
11  2021 Assessing the Impact of Helicobacter pylori Infection and Inflammatory Bowel Disease on Pulse Wave Velocity and Arterial Stiffness. H. pylori, IBD, PWV
12  2021 Bone Metabolism and RANKL/OPG Ratio in Rheumatoid Arthritis Women Treated with TNF-alpha Inhibitors. OPG, sRANKL
13  2021 Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study. ADA, UC
14  2021 Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease. CD, PBMCs
15  2021 Evaluation of factors affecting the frequency and clinical course of COVID-19 in patients using anti-TNF-alpha agents. ICU
16  2021 How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions. IBD
17  2021 Hyperactive neutrophil chemotaxis contributes to anti-tumor necrosis factor-α treatment resistance in inflammatory bowel disease. IL13RA2
18  2021 Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease. ALG, CMC, CS, IBD, IFX
19  2021 Point-of-Care Monitoring of Colitis Using Intestinal Alkaline Phosphatase in Inflammatory Bowel Disease. IAP, IBD, POC
20  2021 Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study. CD, MAdCAM-1, UC
21  2021 Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease. CD, CDAI
22  2021 Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD. CI, IBD, OR
23  2021 The influence of tumour necrosis factor α inhibitors treatment - etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients. COMP, IL-18, IL-6, PsA
24  2021 Use of anti-TNF-α therapy in Crohn's disease is associated with increased incidence of multiple sclerosis. IBD, IRR, MS
25  2020 Aggrecan Turnover in Women with Rheumatoid Arthritis Treated with TNF-alpha Inhibitors. AGC, CS846, RA, TIMP-3, TNFalphaI
26  2020 Approach to Latent Tuberculosis Infection Screening Before Biologic Therapy in IBD Patients: PPD or IGRA? IBD, TB
27  2020 Associations Between Obesity and the Effectiveness of Anti-Tumor Necrosis Factor-alpha Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis. IBD, OR, UC
28  2020 Associations of Platelet Count with Inflammation and Response to Anti-TNF-alpha Therapy in Patients with Ankylosing Spondylitis. AS
29  2020 Biotherapies in Uveitis. ADA, IFX, NIU
30  2020 Chronic Peripheral Inflammation Causes a Region-Specific Myeloid Response in the Central Nervous System. ---
31  2020 Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents. Hb, IBD
32  2020 Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. IBD, ICP
33  2020 PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-alpha therapy-associated demyelinating disorders. CNS, MS, PPMS, RRMS
34  2020 Pregnancy outcomes in partners of male ankylosing spondylitis patients treated with anti-tumour necrosis factor-alpha biologics: real-life results from a single-centre cross-sectional study. AS
35  2020 SAPHO syndrome: the supposed trigger by isotretinoin, the efficacy of adalimumab and the specter of depressive disorder: a case report. DMARDs, IL-1, NSAIDs
36  2020 Successful Anti-TNF-Alpha Therapy for Crohn's Disease After Allogeneic Stem Cell Transplantation: A Case Report. allo-SCT, CBT, CD, GVHD
37  2019 Anti-TNF-alpha therapy alters the gut microbiota in proteoglycan-induced ankylosing spondylitis in mice. ---
38  2019 Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents. CNS, RA
39  2019 Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-alpha Intervention in Pediatric Crohn's Disease. CI
40  2019 Current new challenges in the management of ulcerative colitis. UC
41  2019 Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment. ADA, CRP, IBD, IFX, TC, VitD
42  2019 Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis. IBD
43  2019 Infliximab in the treatment of Budd-Chiari syndrome in Behcet's disease. ---
44  2019 Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children's immunity. IBD
45  2019 Neutrophil Extracellular Traps Sustain Inflammatory Signals in Ulcerative Colitis. CD, DSS, IL-1beta, LPMCs, NC, NETs, UC
46  2019 Radiologic parameters of ankylosing spondylitis patients treated with anti-TNF-alpha versus nonsteroidal anti-inflammatory drugs and sulfasalazine. AS, BASDAI, CRP, ESR, LL, NSAIDs, SSZ
47  2019 Real-world biologic treatment and associated cost in patients with inflammatory bowel disease. CD, IBD, UC, VDZ
48  2019 Refractory Oral Ulcer Responsive to Infliximab: A Case Report. ---
49  2019 Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study. PsA, RA, RDs, RR, TB
50  2019 The Impact of Anti-Tumor Necrosis Factor Alpha Therapy on Postoperative Complications in Pediatric Crohn's Disease. CD, D-C, SSIs
51  2019 The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn's Disease. CD, CI, RR
52  2018 Allergic and Immunologic Perspectives of Inflammatory Bowel Disease. CD, IBD, UC
53  2018 Axial Spondyloarthritis and Autosomal Dominant Polycystic Kidney Disease in Two Siblings: A Rare Cooccurrence. ADPKD, NSAIDs, SpA
54  2018 Biologic Drugs as Analgesics for the Management of Low Back Pain and Sciatica. anti-NGF
55  2018 Combining Anti-TNF-alpha and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. VDZ
56  2018 Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis. ADAs, IFX, RA
57  2018 Effect of education and telephone counseling on adherence to treatment and challenges experienced in anti-TNF-alpha treatment: a pilot study. ---
58  2018 Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients. AUC, CD, OTUs, UST
59  2018 Long-range PCR libraries and next-generation sequencing for pharmacogenetic studies of patients treated with anti-TNF drugs. CD, LR, NGS
60  2018 Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients. DAS28, RA, SLE, SLEDAI
61  2018 No effect of anti-TNF-alpha agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study. IBD, LOS
62  2018 Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. CTCLs
63  2018 Pulmonary aspergillosis after treatment with infliximab in Still's disease and a literature review of Still's disease and pulmonary aspergillosis. ---
64  2018 Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan. NANIU
65  2018 Subclinical cardiac disease in ankylosing spondylitis. AS, csDMARDs, LVGLS, NSAIDs
66  2018 Treatment Failure of TNF-alpha Inhibitors in Obese Patients With Inflammatory Bowel Disease-A Cohort Study. BMI, CI, HRs, IBD, LOR
67  2017 A Comparison of the Efficacy and Tolerability of the Treatments for Sciatica: A Network Meta-Analysis. ODI, SUCRA
68  2017 Antitumor Necrosis Factor-alpha Therapy Associated with Inflammatory Bowel Disease: Three Cases and a Systematic Literature Review. ETN, IBD, JIA
69  2017 Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. RA, RR
70  2017 Endoscopic Recurrence 6 Months After Ileocecal Resection in Children With Crohn Disease Treated With Azathioprine. CD, ICR
71  2017 Evaluation of sleep quality in patients with ankylosing spondylitis and efficacy of anti-TNF-alpha therapy on sleep problems: A polisomnographic study. AS, DA, PSG, PSQI, SQ
72  2017 Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-alpha medications among patients with inflammatory bowel diseases. IBD
73  2017 Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis. CI, HBV, IBD, MD, RR, RR
74  2017 Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barre syndrome after anti-TNF-alpha treatment? Case report and literature review. AS, GBS, IL-17A
75  2017 Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting. IBD, JIA, PYs, SAEs, TAILS
76  2017 The incidence rate of surgical interventions in patients with Crohn's disease treated with anti-tumour necrosis factor biologics. CD, LOR
77  2017 Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-alpha antibodies. CD, MH, SES-CD, TFF3
78  2017 Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease. IBD
79  2016 A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-alpha and Anti-IL-12/23 Agents. ---
80  2016 Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature. CNS, MRI, MS
81  2016 Disruption of Early Tumor Necrosis Factor Alpha Signaling Prevents Classical Activation of Dendritic Cells in Lung-Associated Lymph Nodes and Development of Protective Immunity against Cryptococcal Infection. DC, LALN
82  2016 Endoscopic Complete Remission of Crohn Disease After Anti-Tumor Necrosis Factor-alpha Therapy: CT Enterographic Findings and Their Clinical Implications. CR, CTE
83  2016 Guillain-Barre syndrome during adalimumab therapy for Crohns disease: coincidence or consequence? ---
84  2016 Plasma, urine and ligament tissue metabolite profiling reveals potential biomarkers of ankylosing spondylitis using NMR-based metabolic profiles. AS, KEGG, VIP
85  2016 Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa. HiSCR, HS
86  2016 Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behcet Disease. IFX, vasculo-BD
87  2016 The evaluation of sleep quality and response to anti-tumor necrosis factor alpha therapy in rheumatoid arthritis patients. DA, PSG, PSQI, RA, SQ
88  2016 Update on the mechanisms of action of anti‑TNF-alpha antibodies and their clinical implications in inflammatory bowel disease. IBD
89  2015 AA amyloidosis treated with tocilizumab: case series and updated literature review. CRI, CRP, GFR, RA, REGATE, TCZ
90  2015 Combination of IgG N-glycomics and corresponding transcriptomics data to identify anti-TNF-alpha treatment responders in inflammatory diseases. CD
91  2015 Compliance with risk management plan recommendations on laboratory monitoring of antitumor necrosis factor-alpha therapy in clinical practice. CXR, HBsAg, HCVAb, RMP, TB
92  2015 Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice. Abs, ADE, DENV, ICs
93  2015 Development of Heptylmannoside-Based Glycoconjugate Antiadhesive Compounds against Adherent-Invasive Escherichia coli Bacteria Associated with Crohn's Disease. AIEC, CD, HM, HM, IEC
94  2015 Long-term Outcomes and Risk Factors for Reoperation After Surgical Treatment for Gastrointestinal Crohn Disease According to Anti-tumor Necrosis Factor-alpha Antibody Use: 35 Years of Experience at a Single Institute in Korea. OR
95  2015 pANCA positivity predicts lower clinical response to infliximab therapy among patients with IBD. IBD, pANCA
96  2015 Postoperative Use of Anti-TNF-alpha Agents in Patients with Crohn's Disease and Risk of Reoperation-A Nationwide Cohort Study. ---
97  2015 Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria. PsoRA
98  2015 The anti-TNF-alpha antibody infliximab inhibits the expression of fat-transporter-protein FAT/CD36 in a selective hepatic-radiation mouse model. ---
99  2014 Biologic therapy and surgery for crohn disease. CD
100  2014 Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-alpha therapy. CD